Ark

Ark (Ark Biotech) develops software for computational bioprocessing, offering what it describes as a virtual bioreactor: users upload experimental data they have already generated, create a custom model without coding, and simulate cell culture runs in seconds rather than executing them physically. The platform is positioned across the bioprocess lifecycle, from early-stage process development and scale-up through tech transfer and commercial operations, and is aimed at shortening timelines, reducing the number of physical bioreactor runs, and improving outcomes such as titer and process robustness.

The product exposes more than 25 cell culture trends, including growth metrics (titer, viability, viable cell density), metabolic indicators (pCO2, lactate, ammonia) and soft sensors such as impeller and sparger power-per-volume. Users can run sensitivity analyses and full factorial designs of experiments in silico, explore tens of thousands of process variations in a single action, and have candidate recipes ranked against stated goals and constraints. A scale-up module quantifies cell culture performance across scales and bioreactor configurations using a dynamic bioreactor model, analyzing trends such as pCO2 and osmolality to surface problems early. The system is bioreactor-agnostic, with a library of vessels plus the ability to add custom geometry, impellers and spargers, and includes an interactive "Bioprocess AI Assistant" chatbot for accessing and interpreting results. Ark also references an open-source area alongside its technology, insights and careers pages.

Security and deployment claims include SOC 2 Type II certification, AES-256 encryption at rest and TLS 1.2 or higher in transit, single-tenant AWS hosting with a dedicated VPC, SSO-based authentication with short-lived tokens, secrets management via AWS Secrets Manager and Parameter Store, and a policy that customer data is used only to auto-calibrate models within the customer's own product environment rather than to train Ark's models.

Founding story

Co-founders Zheng Huang and Yossi Quint started Ark to combine domain expertise in biopharmaceutical manufacturing with predictive modeling. Quint began his career as a quantitative researcher in finance, where he saw the effect of predictive modeling; Huang spent over a decade in biopharmaceuticals, including as Director of MSAT at Sanofi, leading tech transfer, process modeling and automation teams, and observed the need for more integrated, data-driven approaches [2].

Business model

Ark sells access to its bioprocess simulation software to biopharmaceutical manufacturers and contract development and manufacturing organizations; the site is structured around booking a demo of the commercially available product, with customer data hosted in single-tenant environments [0][1].

Traction

The company states its software is commercially available and that top biopharma companies and CDMOs use it; it reports SOC 2 Type II certification. A May 2026 insights post reports real-time closed-loop optimization delivering a 43% titer improvement over a historical best [0][1][3].